Syndax Pharmaceuticals (NASDAQ:SNDX) reported quarterly losses of $(0.62) per share which beat the analyst consensus estimate of $(0.65) by 4.62 percent. This is a 134.25 percent decrease over earnings of $1.81 per share from the same period last year.
Charles Schwab’s ‘Transition Year’: Analysts Break Down Q4 Earnings Beat
Charles Schwab shares closed higher on Wednesday, Jan. 17, after the firm reported better-than-expected fourth-quarter earnings.
